Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
1(11%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
1
11%
Ph phase_4
3
33%
Ph not_applicable
1
11%
Ph phase_1
1
11%

Phase Distribution

1

Early Stage

0

Mid Stage

4

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 3Large-scale testing
1(16.7%)
Phase 4Post-market surveillance
3(50.0%)
N/ANon-phased studies
1(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

9

all time

Status Distribution
Active(1)
Completed(4)
Other(4)

Detailed Status

unknown4
Completed4
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (16.7%)
Phase 31 (16.7%)
Phase 43 (50.0%)
N/A1 (16.7%)

Trials by Status

recruiting111%
unknown444%
completed444%

Recent Activity

1 active trials
Showing 5 of 9
recruitingphase_3

Combination of Ranibizumab and Targeted Laser Photocoagulation

NCT04444492
unknownphase_1

A Prospective Study of Ranibizumab in the Treatment of Postoperative Recurrent Vitreous Haemorrhage of Diabetic Retinopathy

NCT05248334
completed

OCTA and Polypoidal Choroidal Vasculopathy

NCT04714242
completed

Evaluation of Retinal and Vascular Features in Coats Disease After Intravitreal Injections of Ranibizumab

NCT04310631
unknownphase_4

Anti-VEGF Therapy Versus Dexamethasone Implant for DME

NCT03999125
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT04444492Phase 3

Combination of Ranibizumab and Targeted Laser Photocoagulation

Recruiting
NCT05248334Phase 1

A Prospective Study of Ranibizumab in the Treatment of Postoperative Recurrent Vitreous Haemorrhage of Diabetic Retinopathy

Unknown
NCT04714242

OCTA and Polypoidal Choroidal Vasculopathy

Completed
NCT04310631

Evaluation of Retinal and Vascular Features in Coats Disease After Intravitreal Injections of Ranibizumab

Completed
NCT03999125Phase 4

Anti-VEGF Therapy Versus Dexamethasone Implant for DME

Unknown
NCT03385382

Ranibizumab Versus Dexamethasone Implant in Diabetic Macular Edema

Completed
NCT03261635Phase 4

Ranibizumab Plus Indomethacin

Completed
NCT01246089Phase 4

Ranibizumab for Myopic Neovascularization

Unknown
NCT01676506Not Applicable

Genetic Polymorphisms in Ranibizumab Treatment in Wet Age-Related Macular Degeneration (AMD)

Unknown

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9